Health Wire Burundi: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Wire Burundi.

February 2026

Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

March 2026

Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

April 2026

Mo	Tu	We	Th	Fr	Sa	Su
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30

Press releases published on February 9, 2026

Feb. 9, 2026

SparingVision Successfully Completes PRODYGY Trial Patient Dosing with SPVN06, its Novel Neuroprotective Gene Therapy

GlobeNewswire

Feb. 9, 2026

Media Advisory: Wear Red Canada highlights heart disease crisis facing Canadian women

GlobeNewswire

Feb. 9, 2026

Avis aux médias : La journée Tout le monde en rouge attire l’attention sur la crise des maladies cardiaques chez les femmes au Canada

GlobeNewswire

Feb. 9, 2026

First Intervention Shown to Lower Alzheimer’s and Dementia Incidence

GlobeNewswire

Feb. 9, 2026

Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update

GlobeNewswire

Feb. 9, 2026

NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury

GlobeNewswire

Feb. 9, 2026

Oruka Therapeutics to Participate in Multiple Upcoming Conferences

GlobeNewswire

Feb. 9, 2026

Inspira Secures Vendor Approval from $12 Billion Revenue HMO (World’s 2nd Largest), Enabling Immediate ART100 Deployment

GlobeNewswire

Feb. 9, 2026

Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy

GlobeNewswire

Feb. 9, 2026

Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knock-off Wegovy® and Ozempic®

GlobeNewswire

Feb. 9, 2026

Integra LifeSciences to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 26, 2026

GlobeNewswire

Feb. 9, 2026

MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)

GlobeNewswire

Feb. 9, 2026

Helsinn and ESTEVE expand their partnership extending the Distribution and Licence Agreement for AKYNZEO® and ALOXI® to Austria

GlobeNewswire

Feb. 9, 2026

Strong clinical data for Breye Therapeutics’ lead oral asset danegaptide presented at Angiogenesis, Exudation and Degeneration 2026 symposium

GlobeNewswire

Feb. 9, 2026

Memo Therapeutics AG Enters into a Collaboration and Option Agreement with CSL for Development of Recombinant Polyclonal IgG Technology

GlobeNewswire

Feb. 9, 2026

Avacta appoints Francis Wilson as Chief Scientific Officer

GlobeNewswire

Feb. 9, 2026

Gute Verkaufszahlen für Cresemba® (Isavuconazol) in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea aus

GlobeNewswire

Feb. 9, 2026

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

GlobeNewswire

Feb. 9, 2026

Communiqué de presse: Le rilzabrutinib de Sanofi a été désigné comme thérapie innovante aux États-Unis et comme médicament orphelin au Japon pour le traitement de l’anémie hémolytique auto-immune à anticorps chauds

GlobeNewswire

Feb. 9, 2026

Press Release: Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia

GlobeNewswire